203 completed, 43 unknown, 33 terminated, 32 recruiting. 345 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 345 | Completed 203, Unknown 43, Terminated 33, Recruiting 32, Withdrawn 17, Not yet recruiting 11, Active not recruiting 4, Enrolling by invitation 2 |
Follow Dyssomnias: new trials by email Literature Review of Dyssomnias trials Research Report on Dyssomnias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Central Apnea in Heart Failure: Physiological Mechanisms to Inform Treatment Trazodone + positive airway pressure (PAP) therapy, Oxygen + positive airway pressure (PAP) therapy - Sleep Disordered Breathing, Able Bodied | Phase 4 | Recruiting | VA Office of Research and Development | 200 | 2026-09-16 | 2026-10-13 |
| A Comparative Effectiveness Study of Positive Airway Pressure (PAP) Therapy, Dental Device, and Atomoxetine-Oxybutynin for Treatment of Obstructive Sleep Apnea in Adults Positive airway pressure (PAP) therapy, Sleep dental device, Atomoxetine-oxybutynin - Obstructive Sleep Apnea (OSA) | Phase 4 | Recruiting | Sairam Parthasarathy | 2400 | 2026-09-04 | 2026-10-19 |
| Suvorexant 3 - PE-PC Suvorexant, Placebo, Prolonged Exposure Therapy for Primary Care (PE-PC) - PTSD - Post Traumatic Stress Disorder, Insomnia | Phase 4 | Not yet recruiting | Northern California Institute of Research and Education | 142 | 2026-09-01 | 2026-07-07 |
| Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease Lemborexant, placebo - Parkinson's Disease, Insomnia | Phase 4 | Not yet recruiting | YangPan | 44 | 2026-08-19 | 2026-06-11 |
| Sleep Quality - Comparing the Effect of Ondansetron or Dexamethasone Given as Routine Prophylaxis Intraoperatively to Prevent Post Operative Nausea and Vomiting (SCORPION) Dexamethasone (IV), Ondansetron iv - Postoperative Sleep Quality, Postoperative Behaviour | Phase 4 | Not yet recruiting | Telethon Kids Institute | 500 | 2026-08-17 | 2026-08-20 |
| Evaluating the Efficacy and Safety of Daridorexant Transition From BZRAs in Insomnia Patients（EASY-TIP） Daridorexant - Insomnia Disorders | Phase 4 | Not yet recruiting | Xuanwu Hospital, Beijing | 156 | 2026-08-01 | 2026-07-29 |
| INFORMing Patients With Oximetry Data to Improve MAD Engagement Narval MRD device, MyNarval intervention (Narval CC MAD + O2 ring + MyNarval smartphone application), - Obstructive Sleep Apnea (OSA) | Phase 4 | Not yet recruiting | ResMed | 120 | 2026-06-01 | 2026-05-04 |
| The Effects of Orexin Antagonism on Fear Extinction in PTSD Suvorexant, Placebo - Insomnia, PTSD | Phase 4 | Not yet recruiting | VA Office of Research and Development | 40120 | 2026-06-01 | 2026-06-02 |
| A SMART Approach to Evaluating the Benefits of Common Prescription and OTC Medications for Insomnia Sleep Hygiene Education, Melatonin IR, 3 mg, Melatonin IR, 5 mg - Insomnia, Insomnia Disorder | Phase 4 | Recruiting | University of Pennsylvania | 1200 | 2026-05-01 | 2026-09-16 |
| Efficacy and Safety of Daridorexant in Patients With Major Depressive Disorder and Insomnia Daridorexant 50 mg, Placebo - Insomnia, Major Depressive Disorder | Phase 4 | Not yet recruiting | Institut d'Investigació Biomèdica de Bellvitge | 134 | 2026-04-01 | 2026-04-29 |
| Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients Conversion to extended-release tacrolimus, Maintenance of immediate-release tacrolimus - Kidney Transplant Recipients, Old Age | Phase 4 | Recruiting | Massachusetts General Hospital | 92 | 2026-03-17 | 2026-05-28 |
| Endotype DIrected Treatment for OSA in Down Syndrome ato-oxy, Oxygen - Obstructive Sleep Apnea (OSA), Down Syndrome | Phase 4 | Recruiting | University of Arizona | 200 | 2026-03-14 | 2026-09-03 |
| Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms Cognitive behavioral therapy for insomnia (CBT-i), Trazodone, Daridorexant - Menopausal Women, Insomnia | Phase 4 | Recruiting | Brigham and Women's Hospital | 1000 | 2026-02-13 | 2026-06-08 |
| Impact of Daridorexant on Sleep, Daytime Alertness, and Smoking Daridorexant 50 mg, Placebo - Smoking, Nicotine | Phase 4 | Not yet recruiting | Legacy Health System | 44 | 2026-02-10 | 2026-01-09 |
| No More Sleepless Nights in Perimenopause Cognitive Behavioural Therapy for Insomnia (CBT-I), Hormone Replacement Therapy (HRT), Sleep Hygiene - Insomnia, Menopause | Phase 4 | Recruiting | Insel Gruppe AG, University Hospital Bern | 54 | 2026-01-01 | 2026-01-13 |
| Compound Ciwujia Granules in the Treatment of Insomnia Compound Ciwujia Granules group, Estazolam, Compound Ciwujia Granules and estazolam - Insomnia Disorder | Phase 4 | Not yet recruiting | Hui Zhu | 1200 | 2026-01-01 | 2025-12-29 |
| Sleeping Through Menopause Estrogens and Progestogens, Cognitive behavioral therapy for insomnia (CBTi), and circadian rhythm therapy - Menopause, Insomnia | Phase 4 | Not yet recruiting | VU University of Amsterdam | 222 | 2025-10-01 | 2025-08-24 |
| Effect of Low Sodium Oxybate (LXB) on Autonomic Symptom Burden in Idiopathic Hypersomnia Patients With Postural Tachycardia Syndrome Low sodium oxybate (LXB), Placebo - Idiopathic Hypersomnia, POTS - Postural Orthostatic Tachycardia Syndrome | Phase 4 | Not yet recruiting | Stanford University | 25 | 2025-10-01 | 2025-07-25 |
| EFFECT OF ZOLPIDEM ON SLEEP QUALITY AND OPIOID CONSUMPTION FOLLOWING PRIMARY TOTAL KNEE ARTHROPLASTY: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL Zolpidem 10 mg tablets, Avocado-soybean unsaponifiables 300 mg - Postoperative Pain Management in Total Knee Arthroplasty | Phase 4 | Completed | Sanatorio Allende | 54 | 2025-08-05 | 2026-09-03 |
| The Role of mGluR5 in CBT-I Cognitive Behavioral Therapy for Insomnia, PET Scan with [11C]ABP688 - Major Depressive Disorder (MDD) | Phase 4 | Recruiting | Stony Brook University | 42 | 2025-08-01 | 2026-02-17 |
Showing 20 of 345. Sign in to see all of them.
Sleep Initiation and Maintenance Disorders (137) · Sleep Apnea, Obstructive (95) · Sleep Apnea Syndromes (66) · Restless Legs Syndrome (30) · Sleep Wake Disorders (20) · Disorders of Excessive Somnolence (14) · Hypertension (14) · Sleep Deprivation (14) · Depression (13) · Heart Failure (9) · Sleep Apnea, Central (9) · Sleep Disorders, Circadian Rhythm (9) · Stress Disorders, Post-Traumatic (9) · Anxiety Disorders (8) · Depressive Disorder, Major (8)
Nervous System Diseases (345) · Sleep Wake Disorders (325) · Sleep Disorders, Intrinsic (324) · Mental Disorders (212) · Respiratory Tract Diseases (153) · Respiration Disorders (147) · Apnea (141) · Pathological Conditions, Signs and Symptoms (100) · Signs and Symptoms (86) · Sleep Apnea Syndromes (81) · Neurologic Manifestations (59) · Cardiovascular Diseases (34) · Parasomnias (31) · Vascular Diseases (27)
Zolpidem (26) · suvorexant (23) · Continuous Positive Airway Pressure (21) · Eszopiclone (20) · ramelteon (16) · Dexmedetomidine (11) · Cognitive Behavioral Therapy (9) · Modafinil (9) · Acetazolamide (8) · Pramipexole (8) · Propofol (8) · Saline Solution (8) · Trazodone (8) · Gabapentin (6) · Melatonin (6)
University of Sao Paulo (9) · VA Office of Research and Development (8) · Hospital Universitario La Paz (7) · Peking University First Hospital (7) · Astellas Pharma Inc (6) · Massachusetts General Hospital (6) · Takeda (6) · University of California, San Diego (6) · University of Zurich (6) · Brigham and Women's Hospital (5) · China Medical University, China (5) · Duke University (5) · Sanofi (5) · Boehringer Ingelheim (4) · Jazz Pharmaceuticals (4)
United States (162) · Brazil (24) · China (20) · Canada (19) · Spain (19) · France (15) · Switzerland (15) · Germany (12) · Italy (12) · Belgium (10) · Japan (8) · Netherlands (7) · United Kingdom (6) · Norway (5) · Sweden (5)
Dong-Xin Wang, MD, PhD (4) · Francisco Garcia-Rio, MD (4) · Konrad E Bloch, MD (4) · Phyllis Diener (3) · Andrew D Krystal, MD (2) · Andrew D Krystal, MD, MS (2) · Andrew Krystal, MD (2) · Armin Steffen, PD Dr. med. (2) · Christopher J Lettieri, MD (2)
PMID 21256799, PMID 33189083, PMID 34739082, PMID 38862381, PMID 10450601, PMID 10678860, PMID 10908222, PMID 10940788, PMID 11208620, PMID 11422885, PMID 11587154, PMID 12748199, PMID 12804680, PMID 14500166, PMID 15187032, PMID 15683149, PMID 16376782, PMID 16494088, PMID 16579514, PMID 16804151, PMID 17068990, PMID 17452537, PMID 17494787, PMID 17496462, PMID 17556718, PMID 17920917, PMID 17921053, PMID 17925431, PMID 17936040, PMID 17975198, PMID 1798888, PMID 18166705, PMID 18172212, PMID 18198262, PMID 18292756, PMID 18347202, PMID 18404673, PMID 18413499, PMID 18417099, PMID 18452788, PMID 18458174, PMID 18458207, PMID 18539753, PMID 18584016, PMID 18584227, PMID 18595959, PMID 18627623, PMID 18647805, PMID 18663661, PMID 18710420
2015 (2), 2019 (1), 2023 (1), 2025 (1), I01CX001814 (1), I01CX001944 (1), I01CX001957 (1), I01RD001576 (1), K23MH066978 (1), P50AG016574 (1), R01AG015866 (1), R01AG028769 (1), R01AG053838 (1), R01AG054521 (1), R01HD114678 (1)